Integra LifeSciences completed its acquisition of Johnson & Johnson's Codman Neurosurgery.
Here are five things to know:
1. The acquisition closed at $1.045 billion less customary adjustments.
2. The Codman Neurosurgery portfolio includes devices for hydrocephalus, neuro-critical care and operative neurosurgery.
3. The Codman neurosurgery products generated about $370 million in 2016 revenue. This acquisition will situate Integra as a leader in neurosurgical products.
4. Integra possesses a portfolio of tissue ablation, dural repair and cranial stabilization products.
5. Additionally, Integra LifeSciences will soon divest its Camino ICP monitoring product line to Natus for $47.5 million. Natus will also gain U.S. rights associated with Integra's fixed pressure shunts and Codman's DURAFORM dural graft implant, standard EVD catheters and CSF collection systems.